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Abtract Epithelial–mesenchymal transition (EMT) is an
important contributor to the invasion and metastasis of
epithelial-derived cancers. While considerable effort has
focused in the regulators involved in the transition process,
we have focused on consequences of EMT to prosurvival
signaling. Changes in distinct metastable and ‘epigentic-
ally-ﬁxed’ EMT states were measured by correlation of
protein, phosphoprotein, phosphopeptide and RNA tran-
script abundance. The assembly of 1167 modulated com-
ponents into functional systems or machines simpliﬁed
biological understanding and increased prediction conﬁ-
dence highlighting four functional groups: cell adhesion
and migration, metabolism, transcription nodes and pro-
liferation/survival networks. A coordinate metabolic
reduction in a cluster of 17 free-radical stress pathway
components was observed and correlated with reduced
glycolytic and increased oxidative phosphorylation enzyme
capacity, consistent with reduced cell cycling and reduced
need for macromolecular biosynthesis in the mesenchymal
state. An attenuation of EGFR autophosphorylation and a
switch from autocrine to paracrine-competent EGFR sig-
naling was implicated in the enablement of tumor cell
chemotaxis. A similar attenuation of IGF1R, MET and
RON signaling with EMT was observed. In contrast, EMT
increased prosurvival autocrine IL11/IL6-JAK2-STAT
signaling, autocrine ﬁbronectin-integrin a5b1 activation,
autocrine Axl/Tyro3/PDGFR/FGFR RTK signaling and
autocrine TGFbR signaling. A relatively uniform loss of
polarity and cell–cell junction linkages to actin cytoskele-
ton and intermediate ﬁlaments was measured at a systems
level. A more heterogeneous gain of ECM remodeling and
associated with invasion and migration was observed.
Correlation to stem cell, EMT, invasion and metastasis
datasets revealed the greatest similarity with normal and
cancerous breast stem cell populations, CD49f
hi/EpCAM
-/lo
and CD44
hi/CD24
lo, respectively.
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Abbreviations
NSCLC Non-small cell lung carcinoma
pY Phosphotyrosine
pS Phosphoserine
pT Phosphothreonine
SCX Strong cation exchange chromatography
C18 Octadecyl silica reverse-phase chromatography
LC Liquid chromatography
EMT Epithelial mesenchymal transition
Introduction
Epithelial–mesenchymal-like transitions (EMT) are impor-
tant in the progression of human carcinomas to a more
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focused on the regulators and processes involved in the
conversion of cells from an epithelial to mesenchymal state,
relatively less effort has been invested toward the conse-
quences of EMT on tumor cell resistance to chemo-, radio-
andtargeted-therapies.Usingmodelsofbothmetastableand
epigenetically-ﬁxed EMT, we have sought to deﬁne at a
molecular level the signaling and survival changes which
occur as a consequence of EMT.
Epithelial-derived tumor cells are capable of transdif-
ferentiation to a more mesenchymal phenotype, a process
resembling EMT [1, 2]. Similarly epithelial tumors may,
directly or through EMT, promote genetic alterations, a
loss of heterozygosity and a wound-like activation of
surrounding or EMT-generated stromal cells [3, 4]. Tumor
localized inﬂammatory cells and stromal ﬁbroblasts can
comprise up to 50–70% of the tumor mass and there is
active multi-directional communication between these
co-evolving [5] cell types that comprise cancer tissue
[6, 7]. For example, tumor cells and inﬁltrating inﬂam-
matory cells promote the formation of desmoplastic stroma
that provide paracrine survival factors to tumor cells [8]
where tumor cells and cancer-associated ﬁbroblasts
become more similar than non-involved ﬁbroblasts.
Inﬂammatory signals in turn can promote EMT [9]. The
activation and hyperproliferation of stromal cells and M2
macrophages facilitate migration of EMT-derived mesen-
chymal-like tumor cells [7, 10, 11]. Mesenchymal-like
tumor cells gain migratory capacity at the expense of
proliferative potential [12]. The migration and invasion of
epithelial-derived carcinoma cells through basement
membrane and into adjacent tissue has been associated
with EMT-like mechanisms [13, 14], acting on single cells
and/or cell sheets [15]. A reverse conversion, a mesen-
chymal-epithelial transition (MET), is thought to be
required to regenerate a proliferative state and form ma-
crometastases resembling the primary tumor at distant sites
[16], though co-migration of EMT and non-EMT cells has
been proposed [17]. There is histological evidence from
patient tumor specimens suggesting that over time select
tumor cells can co-express both proliferative and migratory
programs and exhibit a spindleoid sarcoma-like phenotype
[18]. While pure spindle-cell carcinomas of the lung are
relatively infrequent, representing approximately two per-
cent of NSCLC cases, sarcomatoid elements within tumor
nests are more common and appear to be derived by EMT-
like transitions [19].
The molecular circuitry that controls epithelial—mes-
enchymal transitions in normal embryonic development, in
ﬁbrotic diseases and wound repair, and during tumor pro-
gression has been an area of active investigation. The
tumor heterogeneity, as a consequence of EMT and the
relative insensitivity of mesenchymal-like tumor cells
to targeted-, chemo- and radio- therapies, are important
factors which determine overall patient outcome. Most
notably, tumor cells deriving from EMT-like transitions
have many of the properties of cancer stem cells [20] and
show general resistance to chemotherapy [21, 22]. For
example the EMT phenotype produced by Twist expression
has been shown to inactivate pro-senescence pathways
[23], however in general the molecular mechanisms pro-
moting the anti-apoptotic phenotype associated with EMT
are not well described at a molecular level.
Epithelial tissues normally use autocrine and paracrine
ligand activation of EGFR family and IGF1R signaling to
promote basal cell self-renewal, while in epithelial-derived
cancers abnormal activation of these pathways promotes
tumor expansion and progression. Our previous work has
shown that through EMT-like transitions many carcinoma
cell types acquire abnormal EGFR- and IGF1R-indepen-
dent survival signals to escape anoikis and senescence
during cell detachment and migration [24, 25]. EMT-
derived cells show relative resistance to selective IGF1R/
insulin receptor inhibition [24] or to EGFR inhibition
[26–33] in multiple solid tumor types. This is paradoxical
in that chronic activation of EGFR [34, 35] and IGF1R [36]
can promote EMT-like transitions, but once having
occurred these signals are rendered redundant and alter-
native pathways are engaged in the maintenance of the
mesenchymal-like state. EMT-derived changes in survival,
and metastatic signaling networks has medical importance
in the development of anti-cancer combinations which not
only cause apoptosis of primary tumor cells but also impact
the migratory stem-like cell populations from which cancer
can recur [6, 37, 38].
Here we have investigated both the molecular changes
which initially promote EMT-like transition as well as the
more distant consequences toward survival, metabolic and
cell adhesion signaling networks. At least three distinct
EMT states can be discerned; a pre- or potential-EMT state,
a reversible ‘metastable’ EMT state and an ‘epigenetically-
ﬁxed’ EMT state. EMT-associated networks were identiﬁed
and measured within three inducible ‘metastable’ models,
H358/doxZeb1, H358/doxSnail and H358/TGFb. Similarly
we compared network changes in four NSCLC lines with
either epithelial or ‘epigenetically-ﬁxed’ mesenchymal-like
cell phenotypes. A combination of overlapping experi-
mental approaches, measuring protein, phosphoprotein and
RNA transcript abundance, were used to quantitate signal-
ing network differences between these three different epi-
thelial, metastable mesenchymal and epigenetically-ﬁxed
mesenchymal EMT states. The extensive cellular repro-
gramming associated with EMT resulted in marked shifts in
autocrine survival, cell-junction and metabolic networks,
relevant to drug discovery targeting EMT-like transitions
and mesenchymal stem-like cancer cells.
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Full, detailed experimental and analysis procedures are
provided in Supplemental Information.
Cell culture conditions, doxycycline-inducible EMT
and immunoblotting
Human NSCLC lines H292, H358, Calu6 and H1703 were
cultured in Dulbecco’s modiﬁed Eagle’s medium (DMEM)
with 10% fetal bovine serum (FBS). To promote EMT in
H358 cells TGFb (10 ng/ml) was added to complete media
for 7 days. H358/Snail and H358/Zeb1 were expressed
under the control of the doxycycline inducible CMV pro-
moter (pTRE2puro; invitrogen.com) using the two vector
TET repressor/TET activator system (ptTS, prTA; bla
R)
based on [39]. Doxycycline (0.5 lg/ml) induction of
transgene expression was veriﬁed by immunoblot. Recep-
tor phosphotyrosine content in EMT model cell lines also
was measured by blot e.l.i.s.a. (RTK array; rdsystems.com)
under conditions detailed by the manufacturer.
Confocal microscopy
Cells grown on glass coverslips were washed and ﬁxed with
4% paraformaldehyde in Dulbecco’s PBS followed by per-
meabilization in 0.1% Triton X-100. E-cadherin (Santa
Cruz, sc21791) and vimentin (Chemicon, AB5733) primary
antibodies overnight at room temperature and with diluted
Alexa-ﬂuor 488 or Alexa-ﬂuor 568-conjugated secondary
antibody for 1 h. Nuclei were stained with 40,6-diamidino-
2-phenylindole (300 nmol/l for 5 min). The images were
capturedwithAxioVisionsoftwareonaZeissAxioObserver
microscope and camera and Apotome accessory.
RNA isolation, DNA microarray and RT-PCR analysis
RNA isolated from H358/doxZeb1, H358/doxSnail, H358/
TGFborparentalH358cellswasreversetranscribedintolabeled
cDNAandhybridizedtoU133Plus2orHu1.0exonarraysunder
conditions described by the manufacturer (affymetrix.com).
Two fold RNA abundance differences with detection
Pvaluesof\0.05inanyofthethreeH358modelswereused
as a cutoff. RT-PCR was performed under standard condi-
tions to generate DDCt values for control normalized mes-
enchymal—epithelial RNA transcript abundance ratios.
Preparation of cell extracts and phosphorylation
directed afﬁnity chromatography
Membrane, cytosol and nuclear protein fractions were
prepared, denatured in 8 M urea, reduced, alkylated, sub-
jected to proteolysis with trypsin and desalted on C18 resin.
Anti-phosphotyrosine afﬁnity fractions were isolated
from Triton X-100 cell lysates as previously described [40,
41]. Serine and threonine phosphorylated peptides were
enriched by binding to titanium dioxide. Essentially,
phosphopeptides were enriched on TiO2 beads under acidic
conditions and eluted at high pH, 50% acetonitrile.
Lyophilized TiO2 bound and ﬂow-through fractions were
derivitized with stable isotope tags, isotopically labeled
peptides combined and subjected to SCX ion exchange,
C18 step chromatography, followed LC-tandemMS. Rela-
tive peptide quantitation was performed by stable isotope
peptide derivitization [42].
Peptide identiﬁcation and quantiﬁcation
by LC-tandem MS
Tandem mass spectrometry was performed as previously
described [40]. Proteins were identiﬁed from survey and
product ion spectra using the Paragon algorithm of Pro-
teinPilot (absciex.com) searching human SwissProt and
UniProt protein databases. When multiple protein isoforms
were identiﬁed, only peptides speciﬁc to each detected
isoform were used, which factored in ion counts for
weighting in the protein ratio calculation [43]. Parsimony
of protein results was assured by rigorous protein inference
with the ProGroup algorithm. Protein identiﬁcation com-
plied with the guidelines of [44] where 2 or more unique
isoform-speciﬁc peptides were required for inclusion.
Proteins identiﬁed with C95% conﬁdence with relative
abundances between experimental conditions in the upper
and lower distribution quartiles ([75% or\25%) and with
a t-test P value (for any difference between cell line or
biological condition) of \0.05 were further considered.
Under these conditions false discovery rates (FDR) of
multiple datasets were typically\1% and correctly binned
previously deﬁned benchmark proteins, E-cadherin,
c-catenin, a-catenin, vimentin and ﬁbronectin to their
respective epithelial or mesenchymal cell states. After
protein identiﬁcation at 95% conﬁdence with 2 or more
unique peptides, at least two independent lines of evidence
were required for further consideration.
Phosphoserine and phosphothreonine containing pep-
tides were identiﬁed from TGFb induced H358 cells (1 day
after TGFb treatment, 10 ng/ml) using ProteinPilot v3.0
(absciex.com) and a 95% peptide conﬁdence threshold.
Phosphopeptides were measured by determination of the
median normalized iTRAQ quant tag peak areas for the
biological duplicate samples. EMT modulated phospho-
peptides were selected where the TGFb/control log 2
ratio was[1o r\-1 and where the control N1/control N2
was between log2 -0.5 and 0.5. (Supplemental Tables S9
and S10).
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A schema for the statistical and categorical analysis of pro-
tein, phosphopeptide and RNA transcript data is provided in
SupplementalFig. S1.Changesintheabundanceofproteins,
phosphopeptides and RNA transcripts were compared
between fractions, experiments and models where member-
ship within speciﬁc signaling networks only was established
using two or more independent lines of evidence (Supple-
mentaryTablesS4–S8).Pairwiseandthreewaycomparisons
(Snail-Zeb1 overlap, Snail-TGFb overlap, TGFb-Zeb1
overlapandSnail-TGFb-Zeb1overlaps,aswellasCalu6and
H1703 overlaps) are presented in Supplementary Table S3.
Cellular components modulated through EMT (942 compo-
nents) speciﬁcally in a single model are listed in Supple-
mentaryTable 12.Cross-correlationbetweenconditionsand
the assembly of proteins and encoded proteins within bio-
logical systems and assemblies were used to increase statis-
tical signiﬁcance and facilitate functional understanding.
Proteins and RNA transcripts differentially expressed
between EMT-like cell states were grouped according to
functionusingcurrentliterature,DAVID,IngenuityPathway
Assist (IPA) and STRING. GO terms were annotationally
clusteredusingDAVIDusingasigniﬁcancePvaluecutoffof
0.05(enrichmentscore[1.3)(SupplementalTableS2).Inthe
functionalillustrationsofcomplexesmodulatedduringEMT,
proteins were assembled by protein–protein contacts and
grouped by systems or machines.
Results and Discussion
Epithelial–mesenchymal transition (EMT) involves exten-
sive transcriptional reprogramming [45] to partially or fully
disassemble epithelial cell sheets and promote the invasion,
migration and survival of disseminated mesenchymal-like
tumor cells. In order to understand the biological conse-
quences of these different states of EMT upon cancer cells
we initiated studies to measure the changes in cellular sig-
naling, particularly those pathways which promote cell
survival and resistance to anti-cancer therapies, in models
that represent these different states of EMT. To achieve this
we created three models in which EMT was inducible and
isogenic to the NSCLC H358 cell line, which harbors a
transforming mutation in K-ras, exhibits an epithelial phe-
notype and forms cell–cell junctions. H358 cells stably
transfected with doxycycline-inducible Zeb1 or Snail
cDNAs or exposed to exogenous TGFb (10 nM) over a
7-day period promoted the downregulation of the epithelial
cell marker E-cadherin and the upregulation of the mesen-
chymal cell markers vimentin and ﬁbronectin, characteristic
of an EMT-like transition. Changes were measured in an
isogenic manner, in the presence and absence of the EMT
inducers Zeb1, Snail and TGFb. Thirty-ﬁve individual
clones expressing Zeb1 and 23 clones expressing Snail were
isolated and characterized for transgene induction and the
expression of EMT markers E-cadherin, c-catenin, vimen-
tin, ﬁbronectin, with increasing concentrations of doxycy-
cline added to the culture media (Supplementary Figs. S2
and S3). As a control, three vector only clones were isolated
and characterized in the presence and absence of doxycy-
cline. No change in EMT markers was observed in the
vector control lines with doycycline treatment, either by
Western blot, by proteomic LC-MS/MS analysis or by
microarray analysis (Supplementary Fig. S4). We also
compared these inducible models (H358/doxZeb1, H358/
doxSnail, H358/TGFb and H358/vector control) to four
phenotypically epithelial or mesenchymal-like NSCLC
lines (H292, H358, Calu6 and H1703). The phenotypes of
the epithelial and mesenchymal-like tumor models were
characterized by immunoﬂuorescence microscopy examin-
ing co-staining for E-cadherin and vimentin and by light
microscopy as shown in Fig. 1a. The epithelial models form
cell–cell junctions and express membrane localized E-cad-
herin. In contrast cell models with a mesenchymal pheno-
type (Calu6, H1703, H358/TGFb, H358/Snail and H358/
Zeb1) exhibited a characteristic scattered spindloid mor-
phology (Fig. 1a and Supplementary Fig. S5), lacked
E-cadherin expression and expressed perinuclear interme-
diate ﬁlaments containing vimentin (Fig. 1a) and low levels
of cytokeratins 8 and 18 (not shown). These key protein
changesbetweenepithelialandmesenchymalNSCLCstates
served as an expected benchmark demonstrating EMT-like
changes and allowed for further experiments measuring
signaling network associated with EMT states.
The metastable state of these inducible models was
reﬂected by the complete or partial reversion by removal of
the EMT stimulus, for example by removal of TGFb or
doxycyclinefromtheinducibleH358models,whichrestores
cell–cell junctions and their associations with the actin
cytoskeleton [25]. Withdrawal of doxycycline from the
induced Zeb1 and Snail models similarly reversed EMT
component changes (Supplementary Fig. S8). Continuous
EMT induction for up to 4 months did not appreciably alter
the reversible metastable phenotype. A reversible plastic
metastablestatehasbeenobservedinvivoincellsexpressing
epithelial and mesenchymal splice forms of FGFR2 [46].
Treatmentofthe‘epigenetically-ﬁxed’H1703orCalu6cells
with5-aza-20-deoxycytidine(10 nM)for14 daysresultedin
decreased vimentin protein and increased E-cadherin and
ErbB3 proteins (data not shown), consistent with mesen-
chymal to epithelial transition observed with exposure to
HDAC inhibitors [32]. EMT appears to be a continuum,
whereinthreedistinctstatescanbediscerned;(1)apotential-
EMT state where mesenchymal markers can be expressedin
epithelial sheets with intact cell-junctions; (2) an early
140 Clin Exp Metastasis (2011) 28:137–155
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cally-ﬁxed’ EMT state, irreversible except by chromatin
remodeling [32, 47]. Overall, the model systems used here
represent both epithelial and mesenchymal-like EMT phe-
notypes and metastable and epigenetically-ﬁxed chromatin
states (Fig. 1b).
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Fig. 1 a NSCLC model phenotypes for H292, H358, H358/TGFb,
H358/doxSnail, H358/doxZeb1, Calu6 and H1703 showing phase
contrast and immunoﬂuorescence images using anti-E-cadherin, anti-
vimentin and DAPI co-staining. E-cadherin containing cell junctions
(green) are visible in the epithelial lines H292 and H358. In contrast
the metastable H358/TGFb, H358/doxSnail and H358/doxZeb1 cells
show a loss of E-cadherin expression, a gain of vimentin expression
(red) and a characteristic scattered phenotype. Similarly the
epigentically ﬁxed NSCLC lines Calu6 and H1703 lack E-cadherin
containing cell–cell junctions and express perinuclear vimentin, an
intermediate ﬁlament component. b A scheme depicting EMT states
within the primary tumor mass, in the tumor periphery and in
disseminated tumor cells (DTCs). c Experimental schema for cell
fractionation, protein, phosphoprotein and RNA measurements and
network enrichment
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associated with therapeutic resistance were measured by
global measurement of protein, phosphoprotein and RNA
transcript abundance (Fig. 1c). Component changes were
cross-correlated between cellular fractions, experiments
and models where membership within speciﬁc signaling
networks was established using two or more independent
lines of evidence. Using this stringent cross-correlation
strategy, 218 proteins, 146 phosphoproteins and *1200
RNA transcripts showed differential abundance in the
multiple EMT models. Details and statistics are given in
Supplementary Table S1. One hundred sixty-nine EMT
components were conﬁrmed by either RT-PCR, immuno-
blot or confocal IF (Supplementary Table S8). Further
validation was obtained by comparison of the model sys-
tems to each other and to model systems (EMT, stem cell
and metastatic; Supplementary Table S8) present within
the literature, where few of the EMT components listed in
Supplementary Tables S4–S8 were modulated in one
model alone. Components speciﬁc to a given single model
are listed in Supplementary Table S12. Biological func-
tions were clustered and components perturbed by EMT
assembled into systems to increase signiﬁcance and facil-
itate functional understanding.
Metastable and epigenetically-ﬁxed EMT states
show molecular heterogeneity
Signiﬁcantly enriched functional networks altered between
epithelial and mesenchymal states were identiﬁed by
functional annotation clustering [48, 49] using a signiﬁ-
cance threshold of P\0.05 (Fig. 2a; Supplementary Table
S2). Highly enriched functions altered by EMT included
(1) the marked alterations in cell–cell junction and adhe-
sion networks; (2) the switching of cell proliferation and
survival networks associated with therapeutic resistance;
and (3) the transcriptional networks required for repro-
gramming cell adhesion, cell survival, redox stress and
metabolic pathways. Hierarchical clustering and data
intersection analysis of EMT components modulated by
Zeb1, Snail and TGFb revealed differences between the
three EMT inducers. From a total of 2973 genes modulated
in any of the three H358 EMT models, 16% were shared
between Zeb1, Snail and TGFb models, 13.2% were
shared between Snail and Zeb1, while only 5.6% were
shared between Snail or Zeb1 and the TGFb induced EMT
state (Supplementary Table S3), where the false discovery
rate (FDR) was \1%. EMT components exclusively
modulated in a single model, for example with Zeb1 but
not with Snail or TGFb, are listed in Supplementary Table
S12. We examined both down regulated and up regulated
gene sets independently to ask whether loss and gain of
RNA transcripts were similarly correlated across models,
by calculating overlapping genes or proteins as a percent-
age of non-redundant group size (Fig. 2b; Supplementary
Table S3). Zeb1-Snail overlapping down-regulated genes
were 3-fold greater represented than either TGFb-Zeb1 or
TGFb-Snail overlapping genes; up-regulated genes showed
a 4-fold greater similarity between Zeb1 and Snail com-
pared with TGFb. The subset and clustering analysis of
mRNA abundance data indicated an increased diversity of
modulated genes in the TGFb model relative to the more
closely related Zeb1 and Snail models.
We asked whether the loss of epithelial components was
more uniform than the acquisition of mesenchymal com-
ponents. The concordance of decreased epithelial genes
(20%) in all three inducible H358 models was slightly
higher than the overlap of increased mesenchymal genes
(15% or 1.3-fold). Similarly, comparison of the ﬁxed-state
NSCLC models showed concordance of decreased genes
between EMT states to be 1.4-fold higher than increased
genes (52% vs. 36%, respectively). When we compared the
reversible ‘metastable’ H358 models with the ‘epigeneti-
cally-ﬁxed’ NSCLC lines the trend for concordance of loss
of epithelial markers (10%) over the gain of mesenchymal
markers (2%) was 5-fold. These data indicate that the loss
of epithelial components during EMT showed greater
uniformity than the gain of mesenchymal components.
These data suggest that the enhanced diversity of mesen-
chymal-like tumor cell states could contribute to the
emergence of therapeutically resistant cell populations.
This hypothesis is explored further below in the context of
the extensive reprogramming of cell survival networks
mediated by EMT-like transitions.
There are a number of literature reports of gene signa-
tures correlating EMT, metastatic and stem cell pheno-
types. Comparison of the EMT dataset obtained here with
eighteen datasets from the stem cell, invasion/metastasis
and EMT ﬁelds [50–63] indicate the NSCLC EMT models
were most closely related with normal and cancer-derived
mammary stem cells (Fig. 2c; Supplementary Tables S8
and S11). The greatest intersection of EMT modulated
protein and mRNA abundance, adjusted for dataset size,
were observed for normal mammary stem cells selected for
CD49f
?/EpCAM
low [63] and breast cancer stem cells
selected for CD44
?/CD24
- [51]. These comparisons do
highlight the heterogeneity of EMT and stem cell model
systems and states, suggesting a high degree of plasticity
which may contribute to resistance to single agent anti-
cancer therapies.
Reduced cell cycling in metastable
but not epigenically-ﬁxed EMT states
The metastable EMT phenotype driven by Zeb1, Snail or
TGFb was accompanied by a decrease in the transcription
142 Clin Exp Metastasis (2011) 28:137–155
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These data were consistent with our previous ﬁndings that
after 7 days TGFb mediated EMT in H358 cells increased
cell cycle time 1.7-fold over untreated control cells [64]
where a general decrease in transcript levels for cyclin
isoforms was observed (Supplementary Table S5).
Reduced proliferation also was observed for the H358/
Zeb1 and H358/Snail models but not for the vector control
H358 cells and not in the absence of doxycycline (Sup-
plementary Fig. S6). Attenuated cell cycling with
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Supplementary Table S2.
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Fig. 2 a Enriched functional annotations from combined proteome
and transcript proﬁles. b Heterogeneity of EMT states is in part
dependent on the EMT inducer, where Zeb1- and Snail-induced EMT
were more closely related than TGFb-induced EMT. c EMT dataset
comparison to 18 datasets related stem cell, invasion/metastasis and
EMT characteristics [50–63]. The NSCLC EMT dataset was most
closely related to normal and cancer-derived mammary stem cells,
either by number of overlapping markers or when adjusted for dataset
size (composite score)
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analysis early following TGFb induced EMT (Supple-
mentary Table S9). Within 24 h of TGFb treatment
decreased phosphorylation and activation of cell cycle
kinases and their substrates was observed. For example,
signiﬁcantly reduced phosphorylation of DNA ligase 1
(LIG1) on S66 and S76, required for cell cycle traverse and
DNA repair [65], MCM2 on S139, a site regulating cell
cycle traverse and NUMA1 on S1757 and S1760 were
observed. These data support the reduction in cell cycling
in the H358 background within 24 h of EMT initiation by
Zeb1, Snail and TGFb. This is in marked contrast to
NSCLC epigenetically-ﬁxed mesenchymal cells that show
both the ability to migrate and proliferate. We have shown
previously that there was no difference in proliferation rate,
as measured by BrdU incorporation, when comparing
epithelial and mesenchymal states [31].
Cell-junction assemblies and polarity networks
are repressed with EMT
The loss of cell polarity and cell–cell junctions and the
partial disassembly of epithelial tissues are changes asso-
ciated with cancer progression to an invasive, metastatic
state. The analyses presented here provide a comprehensive
overview of the extensive changes observed in these
important cellular protein complexes during the EMT
process (Fig. 3). As expected [66] a marked and consistent
down-regulation of cell-polarity, tight-junction, adherens-
junction, desmosomal-junction and basement membrane
adhesion components was correlated with a mesenchymal
EMT state, events that served as a technical benchmark to
validate the experimental and statistical approaches used.
Note to verify these ﬁndings, representative protein and
RNA changes were conﬁrmed by immunoblot and TaqMan
RT-PCR, respectively (Supplementary Table S4).
In both inducible H358 and established NSCLC model
systems, a down regulation of thirty-three tight junction
and polarity components was observed (Fig. 3). The
organizing complex required for the establishment of api-
cal-basal polarity in epithelial cells, comprising ParD3,
ParD6, Crb3, Lin7C and LLGL2, was reduced in abun-
dance following EMT, as was tyrosine phosphorylation of
ParD3. Polarity organizing complexes with Par and Crb
family proteins are required for the initiation of tight
junction formation between adjacent epithelial cells [67].
Tight junctions [68] were assembled via the transmem-
brane receptors occludin (OCLN), claudin3 (CLDN3),
claudin7 (CLDN7) and marvelD2 to link adjacent epithe-
lial cells. These receptors in turn establish cell–cell
mechanical strength by tethering to the actin cytoskele-
ton via ZO1/2/3 (TJPs), INADL, CGNL1, a-catenin
(CTNNA1) and eplin (LIMA1). The anchoring of claudin7
junctions to actin ﬁlaments also is thought to occur through
its interaction with the epithelial marker Epcam (TAC-
STD1), a-catenin and a-actinin-4, which were markedly
reduced in abundance in comparing mesenchymal and
epithelial cell states. Similarly proteins involved in the
assembly and linkage of junctional complexes with the
actin cytoskeleton were attenuated with EMT, notably
BAIAP2, DIAPH1 and AHNAK.
Twenty-two cell–cell adherens junction components
were coordinately attenuated with EMT in the multiple
model systems (Fig. 3). In adherens junctions [69], indi-
vidual E-cadherin (CDH1) and P-cadherin (CDH3) pro-
teins located on adjacent cells bind in a calcium-dependent
manner and are linked to their respective actin cytoskele-
tons via b-catenin (CTNB1)/c-catenin (JUP), a-catenin,
eplin protein complex or through JUP, a-catenin (CTN)
and eplin (LIMA1) linkages. Adherens junction assembly
is regulated by protein tyrosine phosphorylation. Both total
and tyrosine phosphorylated forms of a-, b- and d-catenins
were attenuated in the ﬁxed mesenchymal state, while
metastable EMT models showed a more variable loss of
adherens junction components 7 days post induction
(Supplementary Table S4). Additional adherens junction
linkages to the actin cytoskeleton are made through nectin2
(PVRL2), a-catenin and eplin (LIMA1) or through afadin
(MLLT4), LMO7 and a-actinin4 (ACTN4), which were
generally attenuated during EMT.
In desmosomal junctions, desmocollin2 (DSC2) and
desmoglein2 (DCG2) on adjacent cells can form com-
plexes with c-catenin (JUP), a-catenin and eplin (LIMA1)
to link epithelial cells to the actin cytoskeleton [70]. DSG2
and DSC2 proteins are enriched in poorly differentiated
basal epithelial cells. Linkage to c-catenin, plakoglobin2/3
(PKP2/3) and desmoplakin (DSP) provide additional teth-
ering to keratin 7, 8, 18 and 19 containing intermediate
ﬁlaments. These junction complex components were gen-
erally attenuated following EMT, with the exception of
desmoglein, desmocollin and keratins in the single H358/
TGFb model where no change or increased protein abun-
dance was observed, respectively (Fig. 3, Supplementary
Table S4). The loss of phosphotyrosine on cell junction
components generally tracked with overall protein loss
in the ﬁxed state NSCLC models (adjusted r
2 = 0.73,
F\0.0001), but was not signiﬁcant in TGFb induced
H358 cells (adjusted r
2 = 0.32, F\0.06). Taken together
these data indicate that, in the ﬁxed-state models, protein
loss, in part through reduced transcription, can account
for much of the reduction in protein tyrosine phosphate
content. Finally, the loss of a6 integrin, tetraspanin-1
(TSPAN1), laminin-A5 (LAMA5), ladinin (LAD1),
AGR2/3 and MPZL2 (EVA) would be predicted to weaken
cell–cell junctions and decrease cell attachment to base-
ment membrane.
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123Multiple cell junction components were differentially
phosphorylated on serine, threonine or tyrosine early dur-
ing the EMT process, 24 h after initiation of EMT by
addition of exogenous TGFb. We performed phosphopep-
tide selection of iTRAQ labeled peptides by titanium
dioxide (TiO2) afﬁnity selection followed by LC-tandem
MS. Four hundred ninety-six individual phosphopeptides
were identiﬁed using a 95% conﬁdence threshold (Sup-
plementary Table S4). EMT modulation of phosphosite
usage was assessed by Wilcoxon signed rank (P\0.05).
d-catenin (CTNND1) showed increased phosphorylation
on S230, S349 and S352. The propeller protein AHNAK,
known to participate in cell–cell junction formation
through a complex with annexin A2, actin and S100A10,
showed increased phosphorylation on S5448 and S5752,
decreased phosphorylation of S5731. AHNAK homolog
AHNAK2 was signiﬁcantly increased on S857 and
epiplakin (EPPK1) was increased on S3227. These data
suggest the hypothesis that increased serine phosphoryla-
tion on these cytoskeletal/junction proteins, whose abun-
dance will eventually be markedly decreased through
EMT, may promote protein turnover and/or complex dis-
assembly. The network approach used here highlights the
marked attenuation of tight, adherens and desmosomal
junction components, polarity organizing complexes and
changes in adhesion signals in multiple EMT models.
Extracellular matrix remodeling and migratory motor
systems acquired through EMT
We considered what new adhesive and cytoskeletal struc-
tures would compensate for the loss of epithelial cell–cell
junctions, to mitigate anoikis. One such potential mecha-
nism is through an increased dependence on intergin
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Fig. 3 EMT associated cell–cell junction and cell-adhesion/ECM
changes, grouped by system and assembled by protein–protein
contacts. Systems decreased or lost with EMT included tight junctions
(TJ), adherens junctions (AJ), desmosomal junctions (DJ) and
adhesion to basement membrane (BM). Systems increased with
EMT included myosin motor coupling with intermediate ﬁlament and
actin cytoskeletal assemblies, proteases responsible for BM degrada-
tion and extracellular matrix remodeling, and integrin/cadherin
switching allowing new adhesion signals. Components in green were
attenuated during EMT while those in light brown/red were increased
with EMT
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123signaling. In the H358 EMT models integrin switching
to a5b1 and autocrine ﬁbronectin (FN) secretion was
observed and activation of this integrin complex is con-
sistent with increased tyrosine phosphorylation on PTK2/
FAK, paxillin and p130CAS (see below). In addition there
are many changes to the content of the extracellular matrix
surrounding tumor cells. For example, versican (VCAN), a
matrix proteoglycan containing chondroitin sulfate acts to
promote hyaluronan matrix assembly [71] and associates
with lumican. Both versican and lumican were increased in
the three metastable H358 models. Further markedly
increased synthesis of extracellular matrix (ECM) proteins
collagen 14A1 and 5A2, tenacin C, THBS1, SPARC and
ﬁbronectin were noted.
The presence of basement membrane provides a stiff
physical barrier which impedes tumor cell invasion. As part
of the EMT process tumor cells increase the production of
proteases that are able to degrade the surrounding basement
membrane. The observed increased abundance of the
metalloproteinases MMP14 (MT1), MMP9 and ADAM-
TS1 contribute to proteolytic cascades leading to basement
membrane (BM) destruction and tumor cell invasion. In
addition, multiple negative regulators of invasion and
migration were coordinately down regulated, including
CD9, BCAN and maspin (SERPINB5). Increased N-cad-
herin (CDH2) and its associated protein BOC was observed
together with cadherin-11 (CDH11), consistent with cad-
herin switching from E- to N-cadherin early in EMT [72].
Taken together these observations support the notion that
as part of the genetic reprogramming during EMT tumor
cells switch to a pro-invasive/migratory phenotype an
essential component of the metastatic program.
In addition to these changes driving an invasive pheno-
type, numerous changes in proteins involved in cellular
motility were observed. TGFb and Snail mediated EMT in
the H358 background were found to increase cell inva-
siveness and motility in both scratch and Boyden chamber
assays (P\0.0005; Supplementary Fig. S7 and [64]),
thereforewe examined system gains which might contribute
to motility. Microtubule myosin components MYH10,
MYL9, and MYLK together with associated proteins TPM1
and CALD1 were increased in the mesenchymal state,
linkingactin and intermediate ﬁlaments with myosinmotors
in a manner consistent with the acquisition of cell motility
and characteristic of myoﬁbroblasts. Decreased epithelial
myosinMYO5Cwasobserved.L-plastinisanactinﬁlament
protein expressed in ﬁbroblast ﬁlapodia, where phosphory-
lationofS5increasesactinbinding.EarlyinTGFbmediated
EMT phosphorylation of S5 and S257 are increased, which
would activate and recruit L-plastin to an assembling actin
cytoskeleton. S5 is a likely target of PKA [73]. Prominin-2,
like prominin-1 (CD133) a cancer stem cell marker, appears
to play a role in plasma membrane protrusions [74].
Phosphorylationofaserinecore(S114–S118)inprominin-2
is increased early in TGFb EMT. Taken together these
data suggest a coupling of myosin, intermediate and actin
ﬁlaments in EMT mediated motility.
Attenuation of autocrine EGFR family, Met family
and IGF1R signaling networks with EMT
Our previous worked showed that EMT can promote resis-
tance to EGFR and IGF1R tyrosine kinase inhibitors (TKIs)
in multiple carcinoma types [27, 31]. Conﬁrming these
ﬁndings we observed: (1) EGFR, and IGF1R tyrosine
phosphorylation was markedly attenuated in the mesen-
chymal state (Fig. 4a, b); (2) EGF family ligand expression
was attenuated (Supplementary Table S5; [25]); (3) ErbB3,
the preferred phosphatidyl inositol-30 kinase recruiting
partner for EGFR and ErbB2, was transcriptionally silenced
(Fig. 4a, Supplementary Table S5); (4) EGFR total protein
abundance was unchanged regardless of EMT state (Sup-
plementary Table S5). As mesenchymal cells are insensitive
to EGFR inhibition we asked whether EGFR function was
impaired in the mesenchymal state. EGF stimulated SHC
and CBL tyrosine phosphorylation was inhibited by selec-
tive pharmacological EGFR inhibition in both epithelial and
ﬁxed-state mesenchymal lines (Fig. 4c), while a phosphor-
ylation control HSPD1 was unaffected. These data indicate
EGFR is functional and can respond to exogenous ligand in
both epithelial and mesenchymal states, but is only auto-
crine activated in the epithelial state, contributing to EGFR
onco-addiction in cells with an epithelial phenotype.
This extensive dataset allowed us to gain further insight
into the lack of EGFR dependency in the mesenchymal like
state.ForexamplediverseregulatorsofEGFRfunctionsuch
as NKD2, required for export of TGFa to the cell surface
subsequent to proteolytic release and EGFR binding [71],
were decreased during EMT. Similarly LRIG, which
directly interacts with and negatively regulates EGFR sig-
naling [75] and receptor-type tyrosine-protein phosphatase
kappa (PTPRK) that dephosphorylates and inactivates
EGFR signaling [76]were bothincreased. Together with the
observed attenuation of EGF-family ligand synthesis, these
changes in direct EGFR regulators would further reduce
EGFR activity in the mesenchymal state.
Interestingly, both Met and Ron receptor tyrosine
kinases, which bind the ligands HGF and MSP, respec-
tively and are associated with increased cell migration and
metastasis, were decreased in expression and phosphoty-
rosine content in cells with mesenchymal-like phenotype
(Fig. 4a; Supplementary Table S5). The attenuation of
phosphotyrosine-dependent signaling through Met, Ron,
EGFR, ErbB2, ErbB3 and IGF1R were conﬁrmed by blot
e.l.i.s.a. and quantitation of the chemi-luminescent signal
(P\0.01; Fig. 4b). Downstream signaling nodes were
146 Clin Exp Metastasis (2011) 28:137–155
123co-attenuated with the EMT-mediated reduction in Met,
Ron, EGFR and IGF1R kinase activation. These included
multiple SH2, cytoplasmic kinase and ubiquinylation
adapters: pSHC, pGrb2, pGAB1, pPTK6 (Brk), pUBB,
pUBIQ and pNCKAP1. We asked whether attenuated Met
phosphorylation might be attributable to reduced HGF
binding to Met. While no change in HGF transcript abun-
dance was observed, ST14 (matriptase), an extracellular
protease which promotes proHGF activation, was markedly
reduced. SPINT2 and SPINT1, which augment ST14
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123activity, also were attenuated. Paradoxically while EGFR
family, IGF1R and Met signaling can promote EMT, once
transitions occur, signaling from these RTKs is attenuated.
These data suggest that, like EGFR and IGF1R, Met and
Ron play roles early in invasion and migration and are not
required for maintenance of a mesenchymal-like cell state
in multiple NSCLC models.
These observations raise the question as to why mes-
enchymal-like tumor cells simultaneously reduce signaling
through EGFR family, IGF1R and Met RTK networks,
normally important factors for epithelial tissue mainte-
nance. We have shown that the EGFR signaling apparatus
is still intact and can respond to exogenous EGF. A cor-
ollary of these data is that, in vivo, paracrine activation of
EGFR, and possibly IGF1R and Met kinase activities are
still enabled. We propose that autocrine to paracrine
switching allows for chemotactic sensing of growth factor
and cytokine gradients important to invasion. Evidence for
this has been presented in a number of published studies.
For example EMT-derived cells can migrate away from the
tumor mass by chemotactic signaling with recruited mac-
rophages [77]. Tumor cells provide paracrine CSF1 while
recruited tumor associated macrophages secrete EGF
family ligands, whose gradient allows migrational direction
[10]. In this case tumor cells with autocrine EGFR sig-
naling would be incapable of EGF-mediated directional
chemotaxis, a deﬁcit alleviated by EMT-like transition.
Another question that arises from these ﬁndings is what
is promoting cell survival and preventing anoikis or
senescence, in the absence of EGFR family, IGF1R, Met
and Ron signaling, important survival networks for normal
epithelium? We focused on acquired mesenchymal sig-
naling through distinct networks not observed in epithelial
backgrounds.
EMT acquired survival networks
Six major clusters indicating gains of autocrine pathway
activation in mesenchymal-like NSCLC models were
observed (Fig. 5a): IL11 and IL6 mediated gp130-JAK
activation; Gas6 mediated Axl and Tyro3 activation;
ﬁbronectin-mediated a5b1-integrin activation; TGFb- and
BMP1- mediated receptor signaling; and autocrine FGFR
and PDGFR networks were acquired in an EMT dependent
manner. In addition, multiple direct and indirect modula-
tors of cell survival were altered by EMT state.
The cytokine cascades stemming from inﬂammation of
the tumor micro-environment play a key role in cancer
progression and EMT [7, 10, 77]. Among the pro-inﬂam-
matory cytokines unregulated during EMT in the described
models, IL6 and IL11 were of particular interest. IL6 was
observed to increase during EMT in the H358-Snail and
Zeb1 models but not in response to TGFb stimulation
(Supplementary Table S5). In contrast IL-11 was observed
to increase in all three of the H358 based EMT models
(Supplementary Table S5). These cytokines are ligands for
a family of receptors which couple through IL6ST/gp130
to signal through the JAK/STAT3 pathway to induce gene
expression programs. Of interest, we also observe small
increases in the receptors for these cytokines IL6R and
IL6ST (gp130) (Supplementary Table S5) in the Snail
and Zeb1 models. The production of these cytokines and
increased expression of their receptors may have implica-
tions for both autocrine and paracrine signaling mecha-
nisms. Both IL6 and IL11 [78] have been shown to induce
pro-migratory and pro-invasive phenotypes on cancer cells
and so it can be hypothesized that the increased expression
of these cytokines during EMT can contribute to the
invasive nature of mesenchymal-like tumor cells [79]. In
addition, as both of these cytokines can activate the JAK/
STAT signaling pathways it provides a potential mecha-
nistic explanation for the observed resistance of mesen-
chymal-like tumor cells to chemotherapeutic and molecular
targeted therapies. Interestingly, increased IL-6 dependent
signaling has recently been reported to provide resistance
to EGFR targeted therapy [80] with the IL-6 production
being linked to TGFb-mediated EMT [81]. Taken together
these observations suggest that up regulation of IL6 and
IL11 production in cancer cells as they undergo EMT is
linked to a pro-metastatic, tumor progressive phenotype. A
further understanding of the effects of these cytokines on
tumor cells and the tumor microenvironment will lead to
the identiﬁcation of potential routes of therapeutic inter-
vention. These data suggest dual EGFR/JAK-STAT tar-
geting would be required for optimal therapeutic outcome
in metastatic NSCLC with autocrine IL6ST-JAK-STAT
signaling.
The production of these cytokines can also inﬂuence the
tumor microenvironment in a paracrine fashion leading to
enhanced tumor progression. IL6 and IL11 can inﬂuence the
biology of lymphocytes, macrophages, hematopoeitic cells,
endothelial cells and osteoclasts [82]. Of particular interest
is the impact on osteoclasts, whereby IL11 signaling can
induce bone resorption leading to a metastatic niche within
boneamenablefortumorcellgrowth. Indeed, breast cancers
expressing high levels of IL11 show an enhanced level of
bone metastasis compared to those patients whose tumors
express lower levels of IL11 [83]. Multiple cytokine regu-
lators were altered with EMT state, including SIGIRR
(TIR8), an IL1R/Toll-like receptor family member, func-
tions as a negative regulator of inﬂammation [84]. SIGIRR
was down regulated in all three H358 EMT models can
contribute to the aberrant increase inﬂammatory cytokines
in the mesenchymal state. Urocortin 2 (UCR2), a hypoxia
inducible ligand for the corticotrophin receptor with anti-
angiogenic properties [85] was increased in metastable
148 Clin Exp Metastasis (2011) 28:137–155
123EMT. Opposing this function, multiple pro-angiogenic
proteins were increased, notably angiopoietin-1 (ANGPT1),
co-expression of thrombospondins together with the
ADAMTS1 protease [86] and VEGF-C.
Multiple receptor protein kinase networks were acti-
vated in the mesenchymal state. Autocrine Gas6 stimula-
tion of Axl and Tyro3 activity were established from array
and RT-PCR RNA abundance measurements. The data
suggest inhibitors of Axl and Tyro3 activity may show
utility in limiting the survival of shed mesenchymal-like
NSCLC cells. A functional role of autocrine Axl-Gas6
expression in lung [87] and breast cancer [88] progression
has been established. Autocrine activation of FGFR and
PDGFR signaling also was observed in both established
(H1703) and metastable TGFb models, supporting previous
ﬁndings [25, 89]. This increase in kinase activity and
PDGFR autophosphorylation was associated with
increased PDGFR and PDGF RNA transcripts. In meta-
stable Snail and Zeb1 models, FGFR1 and PDGFR tran-
scripts were markedly increased, PDGF was modestly
increased and FGF1 was unchanged or slightly decreased
(Supplementary Table S5). These data support the predic-
tion of kinase activation by autocrine co-expression of
receptor–ligand transcripts. We asked what functional
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and cytokine networks.
Increased signaling through
IL-11/IL-6/gp130, TGFb/
BMP2, Axl/Tyro3, integrin
a5b1, PDGFR and FGFR were
observed. Downstream
activation of BRAF/MAPK1
and PTK2/paxillin signaling
were observed. Components in
green were attenuated during
EMT while those in light
brown/red were increased with
EMT. b Activating MAPK1/Erk
phosphorylation (T185/Y187),
associated with TGFb-induced
EMT, was conﬁrmed by
immunoblot
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123consequence PDGFR and FGFR exerted in the multiple
model systems. While pharmacological inhibition of
PDGFR or FGFR elicited a marked decrease in H1703
proliferation [25, 89], inhibition of PDGFR or FGFR had
little or no activity in the metastable models, despite ini-
tiation of autocrine activation (data not shown). These data
suggest cellular onco-addiction to active PDGFR and
FGFR networks is a trait selected for relatively late fol-
lowing EMT and that PDGFR and FGFR networks are not
required for either the EMT transition itself or for imme-
diate survival following EMT. The activation of TGFbR
signaling is a physiologically relevant and frequent pro-
moter of EMT in many model systems. Increased tran-
scription of TGFb1, 2 and 3 as well as increased levels of
TGFb receptors 1, 2 and BMP receptor 2 were observed.
This was associated with activating phosphorylation of Erk
but not Akt (Fig. 5a, b). However both Snail and Zeb1
metastable models were insensitive to TGFbR inhibition
(data not shown), again suggesting cellular dependence on
TGFb signaling may be a trait selected for relatively late
following EMT or restricted to TGFb-initiated EMT.
As described earlier, H358/TGFb cells markedly upregu-
lated expression of the ﬁbronectin receptor integrin a5b1
together with autocrine ﬁbronectin expression. Autocrine
integrin a5b1 activation was also observed in the committed
mesenchymal-likelinesH460(datanotshown)andsubclones
oftheH292line(datanotshown)supportingitsprominencein
both metastable and ﬁxed mesenchymal states. In the H358/
TGFb model autocrine integrin activation accompanied
tyrosine phosphorylation of PTK2 (FAK), paxillin, BCAR1
(p130CAS) linking this complex to the ﬁlamin A, ﬁlamin B
components of the focal adhesion-actin cytoskeleton. The
BCAR binding adapter protein SH2D3A, a component of the
PTK2/paxillin/actin complex, showed increased phosphory-
lation on S125 in the metastable TGFb model.
Resistance to chemotherapy-induced apoptosis is a
characteristic of mesenchymal-like tumors and lines [21,
22]. Prohibitins-1 and -2 were increased with EMT (Sup-
plementary Table S5) and have been shown to displace
14–3–3 from raf to allow ras localization and activation
[90]. In this regard, increased Erk phosphorylation on the
activation loop was common in both the metastable H358
(Fig. 5b) and ﬁxed state models. Both Erk/2MAPK1 and
p38/MAPK14 showed increased tyrosine phosphorylation
in the H358/TGFb model (Supplementary Table S5),
consistent with increased phosphorylation of Y187 for
MAPK1 (Supplementary Table S9) and enzyme activation.
The down regulation of PKN1 (in all H358 models) and
subsequent reduction in the phosphorylation of TRAF2
may relieve negative control over both NFkB and p38/JNK
pathways. Activation of p38a/MAPK14 and p38IP have
been shown to be required for EMT during mouse gas-
trulation [91]. While cross correlation of individual protein
and gene changes between fractions and experiments
increases the conﬁdence in quantitation, the combined
measurement of system components unequivocally estab-
lish reorganization of receptor protein kinase and integrin
complexes during EMT.
EMT-associated transcription nodes
and alternative splicing
We asked whether subsets of changes observed in mesen-
chymal-like phenotypes could be correlated with speciﬁc
transcription components. We used pathway analysis to
build networks in two ways. Firstly, we built out from EMT
modulated transcription factors to modulated genes and in a
second complementary approach in from EMT modulated
genes back to proposed transcription nodes. The identiﬁed
EMT transcription nodes included NFkB2/RelA, ATF3/
ATF2, Myc, FOXA1/FOXA2, ETS1, NFE2L2/L3, MEF2C,
Snail/Slug [45, 92] and Zeb1/Zeb2 [93, 94]. These networks
are outlined in Fig. 6a, b. The loss of FOXA1 and FOXA2
was recently been shown to result in the loss of E-cadherin
(CDH1) and were required forEMT in pancreas cancer cells
in vitro [95]. Snail is reported to be a critical regulator of
EMTandwasreadilyidentiﬁedasanodeinouranalysis.The
levels of Snail itself were increased in the EMT models, as
were factors reported which inﬂuence its stability and
activity. The serine-threonine kinases PAK1, PAK2 and the
lysyl oxidases (LOX, LOXL1 and LOXL2), which partici-
pate to enhance Snail stability [96], were increased in mes-
enchymal-like NSCLC cells. The dephosphorylation (-2.2
log2) of GSK3a/b on the activating site Y279 also may
contribute to PAK activation and Snail stabilization associ-
atedwithEMT.Supportingthishypothesis,phosphorylation
of PAK2 on S141, an activating phosphorylation site [97],
appeared increased in TGFb mediated EMT (1.5 log2) and
increasedSnailtranscriptswere observed inTGFbandZeb1
models. Finally HDAC7 cytoplasmic-nuclear localization is
regulated by phosphorylation on S486 by PKD or CAMK
and recruitment of 14–3–3 proteins. In TGFb induced EMT
thissiteishypophosphorylated, whichwouldleadtonuclear
localization and repression of target genes.
In addition to transcriptional reprogramming it is clear
that mRNA splicing can change the repertoire of proteins
synthesizedduringEMT.Publishedexamplesofthisinclude
the alternative splicing of FGFR and ENAH (Mena) that
generate proteins with different functional consequences in
epithelial compared to mesenchymal cells [46]. A relatively
largeclusterof24proteinsassociatedwithRNAmaturation,
alternative splicing and RNA export were increased, con-
tributing to post-transcriptional RNA processing associated
with the mesenchymal phenotype and may be functionally
linked to focal adhesion complex changes [98]. In contrast,
mesenchymal cells demonstrated a marked decrease in the
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RBM47, STAU2 and STRBP. Of note, RBM35A and
RBM35B are required for the epithelial splice form of
FGFR1 and FGFR2, known to be alternatively spliced
betweenEMTstates[46]andwherethemesenchymalsplice
form of FGFR shows gain of function.
Cell stress and metabolism
The previous sections have indicated that during metastable
EMT, cells have exchanged proliferative potential for
migratory capability. We asked what metabolic changes
might be associated with this reduction in replicative stress
Fig. 6 a The transcription node
regulating interferon response
was modulated during EMT.
a Reduced free radical
scavenging capacity was
correlated the mesenchymal
state, associated with the
NFE2L2 transcription node.
Components in green were
attenuated during EMT while
those in light brown/red were
increased with EMT.
b Networks regulated during
EMT associated with FOXA,
Snail, Zeb, ATF, NFKB/Rel,
MEF2and Myc transcription
nodes
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ThreefunctionalmetabolicgroupsweremodulatedbyEMT:
(1) the redox-stress pathway was markedly reduced in
capacity; (2) the glycolytic and oxidative phosphorylation
pathwaysappeareddownandupregulated,respectively;and
(3)theprostaglandin/prostacyclinpathwaywasupregulated.
Altered metabolism of cancer cells often leads to the
excess production of reactive oxygen species (ROS) which
are scavenged in part by the glutathione and thioredoxin
pathways [99]. Induction of ROS scavenger pathways has
been associated with resistance to chemotherapeutic agents
which increase free radical production. As mesenchymal
tumor cells show relative resistance to multiple classes of
chemotherapy, the consistent reduction in the abundance of
seventeen members of the ROS scavenger pathway was
unexpected (Fig. 6a). Notably glutathione S-transferase
(GSTP1/O1), perioredoxin (PRDX2/5) and thioredoxin
(TXN) were all attenuated. ROS stress sensing is regulated
in part by phosphorylation and nuclear import/export of the
Cap’n’collarproteinsNFE2L2/L3whichbindtoantioxidant
response elements within target genes. DNA binding is
modulated by multiple proteins upregulated by EMT
(FOSL2, ATF3, ARNTL, PHB and PHB2) [100]. NFE2L2
family activation of anti-oxidant genes is negatively regu-
lated by the dominant negative Cap’n’collar protein
BACH1. BACH1 was increased with metastable EMT and
would block NFE2L2/L3-mediated increases in redox stress
gene expression. Glutathione synthesis genes also can be
regulated by the Myc transcription factor. The decreased
abundance of redox stress pathway components indicate
reduced activation of NFE2L2/L3 transcription and/or Myc
pathways in both metastable and ﬁxed state models. This
ﬁnding is of interest since redox stress can promote EMT-
like transitions [101], but once EMT has occurred, the
activation of free radical induced genes do not appear crit-
ical to a maintenance of the mesenchymal state.
Intersecting DNA damage cellular stress pathways were
similarly decreased with EMT. Histone H2AX, a marker of
DNA repair, is phosphorylated on both S139 and Y142.
The dephosphorylation of Y142 is associated with response
to DNA damage [102, 103]. In both ﬁxed and metastable
models H2AX and H2AZ showed increased phosphotyro-
sine content in the mesenchymal state, indicative of a
reduction in the sensing of DNA damage. While
GADD45b was up regulated in the three metastable mod-
els, taken together the data suggest the GADD45b increase
may reﬂect cell cycle delay rather than DNA damage
response. A coordinate reduction in DNA damage response
and redox stress pathway components was associated with
a mesenchymal-like cell state.
The shift from oxidative phosphorylation to aerobic
glycolysisandincreasedbiosynthesisisahallmarkofcancer
[104]. In turn oxidative stress leads to an excess in ROS
production and an up regulation of glutathione/thioredoxin
scavenger capacity. Through EMT a decrease in ROS
induciblegeneswas observed. Wealsoobserved areduction
inthe abundanceof the glycolyticHK2, PFK, FBP1, PKM2,
ME1, GLUD1 and in glutamate/non-essential amino acid
transporters SLC1A1 and the CD98/4F2 complex (SLC7A5
and SLC3A2), indicative of reduced glycolytic capacity and
reducedoxidativestress.Incontrast,mitochondrialcomplex
I, III and V components NADH dehydrogenase (NDUA9),
Ubiquinol-cytochrome c reductase (UCRC) and ATP syn-
thase subunits 5B/5C1/5D were increased with transition to
amore mesenchymal-like phenotype. Sevenmembersofthe
amino acid metabolism/urea cycle pathway were coordi-
nately decreased during EMT, including CKB, GATM,
GLUD1 and GLUD2, OAT, PRODH, and SAT1. EMT also
resulted in a reduction in transcripts encoding fatty acid
synthase (FASN) and fatty acid hydroxylase (FA2H), sug-
gesting reduced synthesis of palmitate and hydroxy-spin-
golipids. Taken together these data suggest EMT shifts
cellular metabolism to reduce glycolytic capacity, reduce
oxidative stress and limit fatty acid synthesis.
Prostaglandin/prostacyclin metabolism was modulated
by EMT state in a manner consistent with increased pros-
taglandin H2 and prostacyclin availability. The cyclooxy-
genase PTGS2 (COX-2) was increased while carbonyl
reductase was decreased, which together would increase
the abundance of the pro-inﬂammatory cytokine PGE2.
However offsetting decreases in prostaglandin E synthases-
1 and -3 would increase prostaglandin H2 and prostacyclin
abundance. An inﬂammatory microenvironment and ele-
vated COX-2 have been correlated with increased EMT-
like transitions [9, 105].
Conclusions
Here we have developed and extensively analysed a
number of models of the EMT process that reﬂect multiple
different stages of the transition. It is clear from these
studies that analsyes of a single model system by a single
methodology give only a limited insight into the EMT
process as a whole. For this reason we undertook a more
extensive systems biology approach to analyze both
inducible models of EMT in an isogenic background as
well as epigenetically ﬁxed cancer cell lines of both epi-
thelial and mesenchymal phenotypes. From these analyses
it is clear that there are a number of recurring common
themes in the types of transcriptional and protein regula-
tory changes that are observed during EMT. These include
marked changes in the repertoire of cell–cell junctional
proteins, increases in pro-invasive and pro-migratory pro-
teins, changes in the ﬂux through metabolic pathways and a
change in the repertoire of secreted cytokines that modify
152 Clin Exp Metastasis (2011) 28:137–155
123the tumor microenvironment. All of these changes are
controlled through the actions of a number of critical
transcription factors and the networks of factors that they
induce.
Epithelial mesenchymal transitions resulted in marked
changes to cellular survival signaling and metabolic net-
works. A shift from EGFR, IGF1R and Met/Ron activated
signaling networks to a new repertoire of autocrine survival
networks was clear. These included autocrine IL11/IL6-
gp130/JAK2/STAT,ﬁbronectin-integrin,GAS6-Axl/Tyro3,
PDGFR/FGFR/RET and TGFbR networks, often in a het-
erogeneous cell-speciﬁc manner. Preliminary evidence
suggest a model where initial dependence on IL11/IL6-
JAK/STAT, TGFbR and/or ﬁbronectin-integrin signaling in
the early metastable state, gives way to later cell selection
and onco-addiction to Axl, Tyro3, PDGFR, FGFR or RET
networks in the epigenetically-ﬁxed sarcoma-like state
where tumor cells can both proliferate and migrate. The
reductions in oxidative and redox stress networks with EMT
were unexpected and suggest new strategies may be
required to effectively exploit cancer metabolism in epi-
thelial, metastable and ﬁxed-mesenchymal states. The
measured changes in survival and metabolic networks pro-
vide new opportunities to pharmacologically target both
epithelial and mesenchymal tumor cell states, important to
reduce cancer progression and recurrence. These network
changes can be functionally elucidated by systematic large
scale shRNAi screening for EMT phenotype and mesen-
chymal cell survival.
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